[1] 池肇春. 新编实用肝病学.中国医药科学出版社,1994:487-488. [2] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2010年版).实用肝脏病杂志,2011,14(2):81-89. [3] 中华医学会肝脏病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南.中华肝脏病杂志,2006,14(3):161-163. [4] 中华医学会传染病与寄生虫病学分会和肝病学分会.病毒性肝炎防治方案. 中华肝脏病杂志,2000,8(6):324-329. [5] Knodell RR,Ishak KG,Black WC,et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis.Hepatology,1981,1(5):431-436. [6] Yuen MF,Nq IO,Fan ST,et al. Significance of HBV DNA levels in liver histology of HBeAg and anti-HBe positive patients with chronic hepatitis B. Am J Gastroenterol,2004,99:2032-2037. [7] 施军平,范建高. 慢性病毒性肝炎合并脂肪肝的诊治对策. 实用肝脏病杂志,2008,11(4):278-281. [8] 刘宝芳,席志宾. 各型乙型肝炎患者血液HBV DNA水平与临床的关系. 中华传染病杂志,2002,10(1)∶65-67. [9] 刘晓,朱月永. 慢性乙型肝炎合并非酒精性脂肪肝的研究进展. 实用肝脏病杂志,2009,12(4):319-321. [10] Peng D,Han Y,Ding H,et a1. Hepatic steatosis in chronic hepatitis B patients is associated with metabolic factors more than viral factors.J Gastroenterol Hepatol,2008,23(7 Pt 1):1082-1088. [11] Alizadeh AH,Fallahian F,Alavian SM,et a1.Insulin resistance in chronic hepatitis B and C.Indian J Gastroenterel,2006,25:286-289. [12] Oh MK,Winn J,Poordad F. Review article:diagnosis and treatment of non-alcoholic fatty liver disease. Aliment Pharmacol Ther,2008,28(5):503-522. [13] Duseja A,Das A,Dhiman RK,et a1. Mefformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease(NAFLD)not responding to lifestyle interventions. Ann Hepatol,2007,6:222-226. |